Who is sponsoring NCT03788629?

NCT03788629 is sponsored by Hacettepe University.

What drugs are being tested in NCT03788629?

Interventions in NCT03788629: Talocrural joint MWM mobilization, Subtalar joint MWM mobilization.

What condition does NCT03788629 study?

NCT03788629 studies Hemiplegia, Spastic.

Is NCT03788629 still recruiting?

NCT03788629 is currently completed. Last updated 7 April 2020.

Last reviewed 2020-04-07 · How we verify

NCT03788629

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

THE EFFECTS OF SUBTALAR JOINT MOBILIZATION ON PATIENTS WITH CHRONIC STROKE

Completed NA Last updated 7 April 2020

What this trial tests

NA trial testing Talocrural joint MWM mobilization in Hemiplegia, Spastic in 28 participants. Completed in 20 September 2018.

Timeline

30 June 2018

Primary endpoint
20 August 2018

20 September 2018

Quick facts

Lead sponsor	Hacettepe University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	28
Start date	30 June 2018
Primary completion	20 August 2018
Estimated completion	20 September 2018
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Talocrural joint MWM mobilization
Subtalar joint MWM mobilization

Conditions studied

Hemiplegia, Spastic — all drugs for Hemiplegia, Spastic →

Sponsor

Hacettepe University

Who can join

Adults 40 to 65, any sex, with Hemiplegia, Spastic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adequate ankle motion for normal gait ranges from 10° to 15° of dorsiflexion passive range of motion (DF-PROM) to allow the tibia to move over the talus. However, limited ankle mobility is a common impairment in patients with stroke whose DF-PROM has been shown to be approximately half of that in healthy subjects. As a result, these patients have impaired dynamic balance in standing or gait. Mulligan first proposed mobilization with movement (MWM) as a joint mobilization technique. Talocrural MWM to facilitate DF-ROM is performed by applying a posteroanterior tibia glide over a fixed talus while the patient actively moves into a dorsiflexed position while standing. Talocrural MWM has been applied to chronic ankle instability and has been proven effective in improving DF-PROM and standing balance. Subtalar MWM to facilitate DF-ROM is performed by bringing foot to dorsiflexion-abduction-eversion by flexing patient' knee. The effects of subtalar MWM have not been investigated in patients with stroke. Therefore, the purpose of the present study is to examine the effects of subtalar MWM on muscle strength, balance, functional performance, and gait parameters in patients with chronic stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hacettepe University trials

Trials by the same sponsor.

NCT07522060 — Early Functional Response as a Predictor of Clinical Outcomes in Hand Rehabilitation: A Prospective Feasibility Study Us · not yet recruiting
NCT07390162 — The Effect of Changes in the Frequency of Endotracheal Tube Repositioning in Intensive Care Units on the Prevention of O · NA · not yet recruiting
NCT07579676 — DEVELOPMENT AND PSYCHOMETRIC EVALUATION OF THE NEUROCOGNITIVE UPPER EXTREMITY TESTS: A RELIABILITY AND VALIDITY STUDY · not yet recruiting
NCT07524842 — Clinical Performance of Three Different Restorative Materials · NA · not yet recruiting
NCT07439861 — The Effect of Cognitive Dual-Task on Athletic Performance Parameters in Volleyball Players With and Without Chronic Ankl · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03788629 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hacettepe University
Last refreshed: 7 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03788629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing